Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SPARTAN: Apalutamide delays second progression in nonmetastatic CRPC

Key clinical point: Apalutamide was associated with longer time to second progression in nonmetastatic, castration-resistant prostate cancer.

Major finding: Apalutamide was associated with a 45% reduction in risk of second progression.

Study details: An interim analysis of a phase 3, randomized trial in 1207 men with nonmetastatic, castration-resistant prostate cancer.

Disclosures: The SPARTAN trial was funded by Janssen. Dr. Smith disclosed an advisory role, research funding, and travel reimbursement for Janssen and others. Dr. Fizazi disclosed consulting for Janssen and others.


Smith MR et al. ESMO 2019, Abstract 843O.